Efficacy of Fractional Versus Fully Ablative CO2 Laser for Distolateral Onychomycosis: Experience With 20 Patients
Keywords:
onychomycosis, laser, nail, treatmentAbstract
Introduction: Oral antifungals are the treatment choice for onychomycosis, and topical therapies are favored in cases of limited nail involvement. Recently, carbon dioxide (CO2) laser treatment has emerged as an option to enhance the effectiveness of topical therapies.
Objective: Our objective was to compare the efficacy of fractional ablative and fully ablative CO2 laser treatments for distolateral subungual onychomycosis affecting a single toenail and caused by dermatophytes.
Method: The records of 10 patients treated with a single fully ablative CO2 session were matched with those of 10 patients who underwent a single CO2 fractional treatment. All had previously failed topical antifungal lacquers and were discharged with the prescription of topical ciclopirox nail lacquer (8%) for 3 months.
Results: The overall clinical response was 80% versus 60% in the fully ablative compared to the fractional group, with a mean onychomycosis severity index drop of 6.9±5.4 in the fully ablative group and 3.6 ±6.6 in the fractional group computed from baseline to 8.6±1.6 weeks after treatment completion. The relapse rate among responders was 12.5% in the fully ablative and 33.3% in the fractional group after a mean follow-up time of 29.4±2.3 weeks.
Conclusion: Fractional and fully ablative CO2 laser in combination with ciclopirox lacquer could increase theresponse rate in onychomycosis resistant to topical antifungals when systemic therapy is contraindicated or not yet pursued. Fully ablative mode therapy is significantly more effective than fractional (p<0.05). Further studies are needed to identify prognostic response factors and assess the long-term effectiveness of CO2 laser treatment.
References
Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment. J Cutan Med Surg. 2017;21(6):525-539. DOI: 10.1177/1203475417716362. PMID: 28639462.
Gupta AK, Stec N, Summerbell RC, et al. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020;34(9):1972-1990. DOI: 10.1111/jdv.16394. PMID: 32239567.
Westerberg DP, Voyack MJ. Onychomycosis: Current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762-770. PMID: 24364524.
Tosti A, Hay R, Arenas-Guzmán R. Patients at risk of onychomycosis--risk factor identification and active prevention. J Eur Acad Dermatol Venereol. 2005;19 Suppl 1:13-6. DOI: 10.1111/j.1468-3083.2005.01282.x. PMID: 16120200.
Lipner SR, Scher RK. Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835-851. DOI: 10.1016/j.jaad.2018.03.062. PMID: 29959961.
Lipner SR, Scher RK. Onychomycosis: current and investigational therapies. Cutis. 2014;94(6):E21-24. PMID: 25566580.
Litaiem N, Mnif E, Zeglaoui F. Dermoscopy of Onychomycosis: A Systematic Review. Dermatol Pract Concept. 2023;13(1):e2023072. DOI: 10.5826/dpc.1301a72. PMID: 36892372.
Gupta AK, Hall DC, Cooper EA, Ghannoum MA. Diagnosing Onychomycosis: What's New? J Fungi (Basel). 2022;8(5):464. DOI: 10.3390/jof8050464. PMID: 35628720; PMCID: PMC9146047.
Gupta AK, Versteeg SG, Shear NH. Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. J Cutan Med Surg. 2018 ;22(2):129-141. DOI: 10.1177/1203475417733461. PMID: 28954534.
Takahata Y, Hiruma M, Shiraki Y, Tokuhisa Y, Sugita T, Muto M. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week). Mycoses. 2009;52(1):72-76. DOI: 10.1111/j.1439-0507.2008.01531.x. PMID: 18444971.
Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-867. DOI: 10.1016/j.jaad.2018.05.1260.. PMID: 29959962.
Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;16;1(1):CD012093. DOI: 10.1002/14651858. PMID: 31978269.
Leung AKC, Lam JM, Leong KF, et al. Onychomycosis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45. DOI: 10.2174/1872213X13666191026090713. PMID: 31738146.
Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15(6):489-502. DOI: 10.1007/s40257-014-0096-2. PMID: 25257931.
Blume-Peytavi U, Tosti A, Falqués M, et al. A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis. Mycoses. 2022;65(4):392-401. DOI: 10.1111/myc.13392. PMID: 34752667.
Maskan Bermudez N, Rodríguez-Tamez G, Perez S, Tosti A. Onychomycosis: Old and New. J Fungi (Basel). 2023;9(5):559. DOI: 10.3390/jof9050559. PMID: 3723327.
Ebert A, Monod M, Salamin K, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: A multicentre study. Mycoses. 2020;63(7):717-728. DOI: 10.1111/myc.13091. PMID: 32301159.
Shen JJ, Arendrup MC, Verma S, Saunte DML. The Emerging Terbinafine-Resistant Trichophyton Epidemic: What Is the Role of Antifungal Susceptibility Testing? Dermatology. 2022;238(1):60-79. DOI: 10.1159/000515290. PMID: 34058736.
Saunte DML, Hare RK, Jørgensen KM, et al. Emerging Terbinafine Resistance in Trichophyton: Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection. Antimicrob Agents Chemother. 2019;63(10):e01126-19. DOI: 10.1128/AAC.01126-19. PMID: 31383665.
Bortoluzzi P, Prigitano A, Sechi A, et al. Report of terbinafine resistant Trichophyton spp. in Italy: Clinical presentations, molecular identification, antifungal susceptibility testing and mutations in the squalene epoxidase gene. Mycoses. 2023;66(8):680-687. DOI: 10.1111/myc.13597. PMID: 37139949.
Gupta AK, Talukder M, Carviel JL, Cooper EA, Piguet V. Combatting antifungal resistance: Paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis. J Eur Acad Dermatol Venereol. 2023. DOI: 10.1111/jdv.19217. PMID: 37210652.
Gupta AK, Hall DC, Simkovich AJ. How Effective Are Devices in the Management of Onychomycosis?: A Systematic Review. J Am Podiatr Med Assoc. 2023;113(1):21-240. DOI: 10.7547/21-240. PMID: 36905611.
Ma W, Si C, Kasyanju Carrero LM, et al. Laser treatment for onychomycosis: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(48):e17948. DOI 10.1097/MD.0000000000017948. PMID: 31770202.
Shen JJ, Jemec GBE, Arendrup MC, Saunte DML. Photodynamic therapy treatment of superficial fungal infections: A systematic review. Photodiagnosis Photodyn Ther. 2020;31:101774. DOI: 10.1016/j.pdpdt.2020.101774. PMID: 32339671.
Martins Andrade JF, da Cunha Miranda T, Cunha-Filho M, Taveira SF, Gelfuso GM, Gratieri T. Iontophoresis application for drug delivery in high resistivity membranes: nails and teeth. Drug Deliv Transl Res. 2023;13(5):1272-1287. DOI: 10.1007/s13346-022-01244-0. PMID: 36209312.
Kline-Schoder A, Le Z, Zderic V. Ultrasound-Enhanced Ciclopirox Delivery for Treatment of Onychomycosis. Annu Int Conf IEEE Eng Med Biol Soc. 2018;2018:5717-5720. DOI: 10.1109/EMBC.2018.8513552. PMID: 30441634.
Lokajová E, Julák J, Khun J, et al. Inactivation of Dermatophytes Causing Onychomycosis Using Non-Thermal Plasma as a Prerequisite for Therapy. J Fungi (Basel). 2021;7(9):715. DOI: 10.3390/jof7090715. PMID: 34575753.
Gupta AK, Venkataraman M, Joshi LT, Cooper EA. Potential use of microwave technology in dermatology. J Dermatolog Treat. 2022;33(7):2899-2910. DOI: 10.1080/09546634.2022.2089333. PMID: 35699665.
Carney C, Tosti A, Daniel R, et al. A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch Dermatol. 2011;147(11):1277-1282. DOI: 10.1001/archdermatol.2011.267. PMID: 22106113.
Gupta AK, Stec N. Recent advances in therapies for onychomycosis and its management. F1000Res. 2019;8:F1000 Faculty Rev-968. DOI: 10.12688/f1000research.18646.1. PMID: 31297182.
Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J Eur Acad Dermatol Venereol. 2017;31(7):1111-1118. DOI: 10.1111/jdv.14212. PMID: 28294418.
Rajbanshi B, Shen L, Jiang M, et al. Comparative Study of Traditional Ablative CO2Laser-Assisted Topical Antifungal with only Topical Antifungal for Treating Onychomycosis: A Multicenter Study. Clin Drug Investig. 2020;40(6):575-582. DOI: 10.1007/s40261-020-00914-6. PMID: 32314298.
Bhatta AK, Keyal U, Huang X, Zhao JJ. Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis. J Am Acad Dermatol. 2016;74(5):916-923. DOI: 10.1016/j.jaad.2015.12.002. PMID: 26874820.
Shi J, Li J, Huang H, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with terbinafine hydrochloride 1% cream for the treatment of onychomycosis. J Cosmet Laser Ther. 2017;19(6):353-359. DOI: 10.1080/14764172.2017.1334925. PMID: 28557542.
Lee SK, Kim HY, Lee JH, Lee UH, Kim MS. Real-world effectiveness of a fractional CO2laser with topical antifungal agents for the treatment of onychomycosis. Dermatol Ther. 2022;35(6):e15498. DOI: 10.1111/dth.15498. PMID: 35388594.
Han Y, Wang Y, Zhang XR, Chen J, Li XD. The effects of CO2 laser and topical agent combination therapy for onychomycosis: A meta-analysis. Dermatol Ther. 2021;34(6):e15136. DOI: 10.1111/dth.15136. PMID: 34538013.
Ortner VK, Nguyen N, Brewer JR, Solovyeva V, Haedersdal M, Philipsen PA. Fractional CO2laser ablation leads to enhanced permeation of a fluorescent dye in healthy and mycotic nails-An imaging investigation of laser-tissue effects and their impact on ungual drug delivery. Lasers Surg Med. 2022;54(6):861-874. DOI: 10.1002/lsm.23541. PMID: 35451510.
Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther. 1997;19(3):559-569. DOI: 10.1016/s0149-2918(97)80140-3. PMID: 9220219.
Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4 Suppl):S70-80. DOI: 10.1067/mjd.2000.109071. PMID: 11051136.
Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. J Dermatol. 2010;37(2):137-139. DOI: 10.1111/j.1346-8138.2009.00773.x. PMID: 20175847
Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;2007(3):CD001434. DOI: 10.1002/14651858.CD001434.pub2. PMID: 17636672; PMCID: PMC7073424.
Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution--an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1985;10(2):111-115. DOI: 10.1111/j.1365-2230.1985.tb00537.x. PMID: 3156698
Published
Issue
Section
License
Copyright (c) 2024 Laura Gnesotto, Bianca Maria Piraccini, Michela Starace, Luigi Naldi, Guido Mioso, Andrea Sechi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
